Scientific Publications

HIV/AIDS and AntiViral-HyperActivation Limiting Therapeutics (AV-HALT)

Lova, L., Groff, A., Ravot, E., Comolli, G., Xu, J., Whitman, L., Lewis, M., Foli, A., Lisziewicz, J., Lori, F.: Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes. AIDS, Jan 28;19(2): 137-144, 2005.

Lori, F., Pollard, R.B., Whitman, L., Bakare, N., Blick, G., Shalit, P., Foli, A., Peterson, D., Tennenberg, A., Schrader, S., Rashbaum, B., Farthing, C., Herman, D., Norris, D., Greiger, P., Frank, I., Groff, A., Lova, L., Asmuth, D., Lisziewicz, J.: Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. AIDS Res Hum Retroviruses. 21(4): 263-272, 2005.

Lori, F., Foli, A., Groff, A., Lova, L. MS, Whitman, L., Bakare, N., Pollard, R.B., Lisziewicz, J.: Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms AIDS. Jul 22;19(11): 1173-8, 2005.

Lori, F., Foli, A., Lisziewicz, J.: Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options. Current Opinion in HIV and AIDS 2:14-20, 2007.

Lori, F., Foli, A., Kelly, L.M., Lisziewicz, J.: ViroStatics: A New Class of Anti-HIV Drugs. Curr Med Chem. 14: 233-41, 2007.

Maserati, R., Foli, A., Tomasoni, L., Sighinolfi, L., Maggiolo, F., Sacchini, D., Di Pietro, M., Bertelli, D., Tinelli, C., and Lori, F.: Effects of Structured Treatment Interruptions on Metabolilc, Anthrompometric, Immunologic, and Quality of Life Outcomes in HIV-Positive Adults on HAART. Current HIV Research 5:337-43, 2007.

Foli, A., Maiocchi, M.A., Lisziewicz, J., and Lori, F. A Checkpoint in the Cell Cycle Progression as a Therapeutic Target to Inhibit HIV Replication. J Infect Dis. 196(9):1409-15, 2007.

Lori, F. Treating HIV/AIDS by reducing immune system activation: the paradox of immune deficiency and immune hyperactivation. Current Opinion in HIV and AIDS 3:99-103, 2008.

Lori F, DeForni D, Stevens M. Development of VS411, a virostatic fixed-dose combination (FDC) designed to inhibit both HIV and immune hyperactivation.  Poster abstract 11. HIV DART 2008: frontiers in drug development for antiretroviral therapies, 9-12 December 2008, Rio Grande, Puerto Rico.


PHPC Assay

S. A. Calarota, A. Foli, R. Maserati, V. La Rosa , F. Baldanti, S. Paolucci, C. M. Tsoukas, J. Lisziewicz, F. Lori  "Antigen-specific T Lymphocytes with High Proliferative Capacity Inversely Correlate with Viral Replication in Chronically Untreated HIV-1-infected Individuals" Poster # P2.4/02/BPD, 11th European AIDS Conference / EACS, Madrid, Spain, Oct 24-27, 2007.

Calarota, S.A., Foli, A., Maserati, R., Baldanti, F., Paolucci, S., Young, M.A., Tsoukas, C.M., Lisziewicz, J., and Lori, F. HIV-1-specific T-cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 180:5907-5915, 2008.